Diffusion and perfusion imaging in subacute neurotoxicity following high-dose intravenous methotrexate

被引:28
作者
Eichler, April F.
Batchelor, Tracy T.
Henson, John W.
机构
[1] Massachusetts Gen Hosp, Pappas Ctr Neurooncol, Boston, MA 02114 USA
[2] Massachusetts Gen Hosp, Neurol Serv, Boston, MA 02114 USA
[3] Massachusetts Gen Hosp, Div Neuroradiol, Boston, MA 02114 USA
[4] Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA
[5] Harvard Univ, Sch Med, Boston, MA 02115 USA
关键词
adult; diffusion; methotrexate; neurotoxicity;
D O I
10.1215/15228517-2007-015
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Methotrexate (MTX) is a widely used chemotherapeutic agent that can cause acute, subacute, and chronic neurological complications. Subacute MTX neurotoxicity is manifest by abrupt onset of focal cerebral dysfunction occurring days to weeks after MTX administration, usually in children. We describe the neuroimaging features of an adult patient with primary CNS lymphoma who presented with transient aphasia and right hemiparesis 12 days after receiving intravenous highdose MTX (8 g/m(2)) chemotherapy. Imaging within 1 h of symptom onset showed bilateral symmetrical restricted diffusion involving white matter of the cerebral hemispheres. CT angiogram and dynamic susceptibility MRI showed no evidence of vasospasm or perfusion defect. MRI five days later showed nearcomplete resolution of the abnormalities. MRI 3 months later showed normal diffusion but new hyperintense T2-weighted signal changes in the subcortical white matter corresponding to previous areas of restricted diffusion. The absence of vascular or perfusion abnormalities suggests that transient cytotoxic edema in white matter may explain the syndrome of subacute MTX neurotoxicity.
引用
收藏
页码:373 / 377
页数:5
相关论文
共 28 条
  • [1] TRANSIENT CEREBRAL-DYSFUNCTION FOLLOWING CHEMOTHERAPY FOR OSTEOGENIC-SARCOMA
    ALLEN, JC
    ROSEN, G
    [J]. ANNALS OF NEUROLOGY, 1978, 3 (05) : 441 - 444
  • [2] ASATO R, 1992, CANCER, V70, P1997, DOI 10.1002/1097-0142(19921001)70:7<1997::AID-CNCR2820700732>3.0.CO
  • [3] 2-G
  • [4] BLEYER WA, 1981, CANCER TREAT REP, V65, P89
  • [5] White matter and cerebral metabolite changes in children undergoing treatment for acute lymphoblastic leukemia:: Longitudinal study with MR imaging and 1H MR spectroscopy
    Chu, WCW
    Chik, KW
    Chan, YL
    Yeung, DKW
    Roebuck, DJ
    Howard, RG
    Li, CK
    Metreweli, C
    [J]. RADIOLOGY, 2003, 229 (03) : 659 - 669
  • [6] MR FINDINGS IN METHOTREXATE-INDUCED CNS ABNORMALITIES
    EBNER, F
    RANNER, G
    SLAVC, I
    URBAN, C
    KLEINERT, R
    RADNER, H
    EINSPIELER, R
    JUSTICH, E
    [J]. AMERICAN JOURNAL OF ROENTGENOLOGY, 1989, 153 (06) : 1283 - 1288
  • [7] Fisher MJ, 2005, AM J NEURORADIOL, V26, P1686
  • [8] Diffusion-weighted MRI correlates of subacute methotrexate-related neurotoxicity
    Haykin, ME
    Gorman, M
    van Hoff, J
    Fulbright, RK
    Baehring, JM
    [J]. JOURNAL OF NEURO-ONCOLOGY, 2006, 76 (02) : 153 - 157
  • [9] Posterior leukoencephalopathy following, intrathecal chemotherapy with MRA-documented vasospasm
    Henderson, RD
    Rajah, T
    Nicol, AJ
    Read, SJ
    [J]. NEUROLOGY, 2003, 60 (02) : 326 - 328
  • [10] JAFFE N, 1985, CANCER, V56, P1356, DOI 10.1002/1097-0142(19850915)56:6<1356::AID-CNCR2820560623>3.0.CO